AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

GLOBALDATA PLC

Regulatory Filings Jan 7, 2025

7674_rns_2025-01-07_fde32516-4ace-4fb1-95a4-b1b2249ab398.html

Regulatory Filings

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 3159S

GlobalData PLC

07 January 2025

7 January 2025

GlobalData Plc

Acquisition Updates

Healthcare Division: Acquisition of Deallus

GlobalData Plc ('GlobalData' or the 'Group'), a leading data, analytics, and insights platform, today announces further progress in its M&A strategy.

The Group announces that it has completed the acquisition of Deallus, a market-leading competitive intelligence solutions provider focused on the global life sciences sector.

During its 20 years in business, Deallus has built deep sector expertise through supporting clients in key therapy areas, including Oncology, Neuroscience, Vaccines, Rare Diseases, Cell & Gene, and Immunology. The combination creates the opportunity for the Group to build deeper, more embedded relationships with major brands within the pharmaceutical sector and creates the potential for GlobalData to deliver more value to our clients.

The transaction was funded by the Group's new recently announced debt facilities and completed on 31 December 2024. This represents the fourth acquisition completed in H2 2024, in addition to the acquisitions of Business Trade Media International, LinkUp and Celent, which also completed on 31 December 2024 following the satisfaction of certain closing conditions.

The Group will issue an update on its trading and FY24 results on 14 January 2025 and will provide further detail on the positive impact of its recent M&A activity.

Mike Danson, CEO of GlobalData PLC, commented: "This acquisition further enhances our capabilities in delivering life sciences solutions, allowing us to deliver even more comprehensive insights and services to our clients. Deallus's deep sector expertise and client-first mindset perfectly align with our mission to empower decision-makers in navigating the complexities of the healthcare landscape. Together, we are poised to drive remarkable growth and deliver exceptional value to our stakeholders."

ENQUIRIES

GlobalData Plc
Mike Danson, Chief Executive Officer 0207 936 6400
Graham Lilley, Chief Financial Officer
J.P. Morgan Cazenove (Nomad, Joint Broker) 0203 493 8000
Bill Hutchings
Mose Adigun
Panmure Liberum (Joint Broker) 0203 100 2000
Rupert Dearden
Dougie McLeod
Investec Bank plc (Joint Broker)

Henry Reast

Virginia Bull
0207 597 5970
FTI Consulting (Financial PR) 0203 727 1000
Edward Bridges [email protected]
Dwight Burden
Emma Hall

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACQDGGDBUSGDGUL

Talk to a Data Expert

Have a question? We'll get back to you promptly.